Compounds > locustamyoinhibiting peptide, locusta migratoria
Page last updated: 2024-12-11

locustamyoinhibiting peptide, locusta migratoria

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

locustamyoinhibiting peptide, Locusta migratoria: amino acid sequence given in first source; suppresses spontaneous contractions of hindgut and oviduct of Locusta migratoria [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5748485
MeSH IDM0198297

Synonyms (11)

Synonym
ala-trp-gln-asp-leu-asn-ala-gly-trp-nh2
lom-mip
lom-mip protein, locusta migratoria
l-tryptophanamide, l-alanyl-l-tryptophyl-l-glutaminyl-l-alpha-aspartyl-l-leucyl-l-asparaginyl-l-alanylglycyl
locusta myoinhibiting peptide, locusta migratoria
138168-63-5
locusta myoinhibiting peptide
locustamyoinhibiting peptide, locusta migratoria
(3s)-4-[[(2s)-1-[[(2s)-4-amino-1-[[(2s)-1-[[2-[[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-aminopropanoy
DTXSID60160513
(3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-indol-3- yl)propanoyl]amino]-4-carbamo
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (85.71)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.10 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyrrolidonecarboxylic acid
Pyrrolidonecarboxylic Acid: A cyclized derivative of L-GLUTAMIC ACID. Elevated blood levels may be associated with problems of GLUTAMINE or GLUTATHIONE metabolism.. 5-oxo-L-proline : An optically active form of 5-oxoproline having L-configuration.		2105-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid		algal metabolite
neomyosuppressin
neomyosuppressin: myoinhibiting neuropeptide from the grey fleshfly, Neobellieria bullata & Drosophila		1.9810
crustacean cardioactive peptide
crustacean cardioactive peptide: cardioactive neuropeptide, from the nervous system of the shore crab carcinus maenas; do not confuse with CCAP (katacalcin), a calcitonin carboxyl-terminal flanking peptide		210
ConditionIndicatedRelationship StrengthStudiesTrials
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.940